Christopher Wrocklage
Pioneer (United States)(US)Q Therapeutics (United States)(US)
Publications by Year
Research Areas
CRISPR and Genetic Engineering, CAR-T cell therapy research, Rheumatoid Arthritis Research and Therapies, Virus-based gene therapy research, Cytokine Signaling Pathways and Interactions
Most-Cited Works
- → Selective functional inhibition of JAK‐3 is sufficient for efficacy in collagen‐induced arthritis in mice(2010)74 cited
- → Imidazo[1,5-a]quinoxalines as irreversible BTK inhibitors for the treatment of rheumatoid arthritis(2011)63 cited
- → Rational design of a SOCS1-edited tumor-infiltrating lymphocyte therapy using CRISPR/Cas9 screens(2023)33 cited
- → 204 KSQ-004: Unbiased pair-wise discovery of SOCS1 and Regnase-1 as the top CRISPR/Cas9 dual-edit combination enhancing in vivo TIL potency against solid tumors(2021)5 cited
- → Rational design of a SOCS1-edited tumor infiltrating lymphocyte therapy for solid tumors using CRISPR/Cas9 screens(2023)5 cited
- → 186 Development of KSQ-001, an engineered TIL (eTIL) therapy for solid tumors through CRISPR/Cas9-mediated editing of SOCS1(2021)2 cited
- → Abstract 2175: KSQ-001: A CRISPR/Cas9-engineered tumor infiltrating lymphocyte (eTILTM) therapy for solid tumors(2020)2 cited
- → The novel and selective JAK3 inhibitor WYE-152038 is highly efficacious in a mouse model of rheumatoid arthritis(2009)
- → 1378 Discovery and characterization of PM-4321, a selective inhibitor of the aryl hydrocarbon receptor (AHR) with anti-tumor immunomodulatory effects(2023)